Circadian influence in cardiovascular disease (Part 1).
Valle
G A
GA
Department of Medicine, University of Miami School of Medicine, Florida.
Lemberg
L
L
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002940:Circadian Rhythm / Q000502:physiology*; D003327:Coronary Disease / Q000188:drug therapy / Q000503:physiopathology*; D004334:Drug Administration Schedule; D005395:Fish Oils / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009566:Nitrates / Q000627:therapeutic use; D009569:Nitric Oxide / Q000502:physiology; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use
D000316:Adrenergic alpha-Agonists; D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D005395:Fish Oils; D009566:Nitrates; D010975:Platelet Aggregation Inhibitors; D009569:Nitric Oxide